Caroline Hopkins Legaspi

Researchers analyzed two dozen studies and found similar rates of second primary cancers in patients receiving CAR T-cell and standard therapies. 

Phase III data presented at the WCLC suggests the new VEGF and PD-L1 inhibitor could prolong progression-free survival versus Merck's anti-PD-1 blockbuster. 

Adaptimmune's recent Tecelra approval further bolsters confidence in the feasibility of commercial approval for autologous cell therapies in solid tumors. 

New analyses from the Phase I trial of mRNA-4157 shed light on lasting immune responses, toxicity profiles, and treatment feasibility. 

The drugmaker updated investors on its three-pronged strategy to diversify its pipeline and not overly rely on its top-selling blockbuster checkpoint inhibitor.

In the first half of the year, sales of the injectable formulation of HER2-targeted agent grew 60 percent at CER, compared to H1 2023. 

Growth of the prostate cancer radiopharmaceutical was exponential following approval, but has now settled, leading Novartis to ramp up promotional efforts. 

The firm is encouraged by the MAT2A inhibitor's commercial prospects after seeing its efficacy as a monotherapy in some MTAP-null bladder and lung cancer patients. 

Researchers say the rare subtype of gamma-delta T-ALL, characterized by the STAG2/LMO2 rearrangement, may be vulnerable to this class of drugs.

After three years of follow-up, mRNA-4157 plus Keytruda led to a 49 percent reduction in the risk of disease recurrence or death versus Keytruda alone.